Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1156-1164

  Rojo, F ^a,b   Garcia Parra J ^a   Zazo, S ^b   Tusquets, I ^a   Ferrer Lozano, J ^c   Menendez, S ^a   Eroles, P ^c   Chamizo, C ^b   Servitja, S ^a   Ramirez Merino N ^b   Lobo, F ^b   Bellosillo, B ^a   Corominas, J M ^a,d   Yelamos, J ^a   Serrano, S ^a,d   Lluch, A ^c,e   Rovira, A ^a   Albanell, J ^a,d  

^a HOSPITAL DEL MAR   (Spain)

^b 28400 Madrid   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Valencia Central University   (Spain)

Author keywords

Biomarker; Breast cancer; PARP 1; Prognosis; Triple negative

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 84858957528     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr361     Document Type: Article

References (54)

1. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-528.
2. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999; 342(Pt 2): 249-268.
3. Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 2008; 13: 3046-3082.
4. Schreiber V, Ame JC, Dolle P et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002; 277: 23028-23036.
5. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA doublestrand break repair. J Clin Oncol 2008; 26: 3785-3790.
6. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010; 7: 508-519.
7. Frizzell KM, Kraus WL. PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2? Breast Cancer Res 2009; 11: 111.
8. Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 2005; 386: 119-125.
9. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
10. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
11. De Soto JA, Deng CX. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int J Med Sci 2006; 3: 117-123.
12. Inbar-Rozensal D, Castiel A, Visochek L et al. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Res 2009; 11: R78.
13. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
14. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581.
15. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
16. O'Shaughnessy LSS, Danso MA, Rugo HS et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; (Suppl): 29. (Abstr 1007).
17. Leung M, Rosen D, Fields S et al. Poly (ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 2011 March 11 [epub ahead of print], doi: 10.2119/molmed.2010.00240.
18. Goncalves A, Finetti P, Sabatier R et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat 2011; 1: 273-281.
19. Bieche I, de Murcia G, Lidereau R. Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res 1996; 2: 1163-1167.
20. Ossovskaya V, Koo IC, Kaldjian E et al. Upregulation of poly(ADP-ribose) polymerase-1 (PARP-1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010; 1: 812-821.
21. Domagala P, Huzarski T, Lubinski J et al. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011; 3: 861-869.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 1991; 19: 403-410.
23. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
24. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
25. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220.
26. Rojo F, Gonzalez-Navarrete I, Bragado R et al. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 2009; 15: 3530-3539.
27. Aoufouchi S. Monoclonal antibodies A4.3.4; A6.4.12; B5.3.9; B15.4.13 antipoly(ADP-ribose)polymerase. Hybridoma 1997; 16: 583.
28. Levenson RM, Fornani A, Loda M. Multispectral imaging and pathology: seeing and doing more. Expert Opin Med Diagn 2008; 2: 1067-1081.
29. Generali D, Buffa FM, Berruti A et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 2009; 27: 227-234.
30. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
31. Brustmann H. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol 2007; 26: 147-153.
32. Csete B, Lengyel Z, Kadar Z, Battyani Z. Poly(adenosine diphosphate-ribose) polymerase-1 expression in cutaneous malignant melanomas as a new molecular marker of aggressive tumor. Pathol Oncol Res 2009; 15: 47-53.
33. Nosho K, Yamamoto H, Mikami M et al. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer 2006; 42: 2374-2381.
34. Staibano S, Pepe S, Lo Muzio L et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005; 36: 724-731.
35. Loibl S, Mueller B, Von Minckwitz G et al. PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. J Clin Oncol (Meeting Abstract) 2010; 28: 10511.
36. Crawley JJ, Furge KA. Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol 2002; 3: 1-8.
37. Oei SL, Shi Y. Transcription factor Yin Yang 1 stimulates poly(ADP-ribosyl)ation and DNA repair. Biochem Biophys Res Commun 2001; 284: 450-454.
38. Durocher F, Labrie Y, Ouellette G, Simard J. Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. J Hum Genet 2007; 52: 963-977.
39. Cao WH, Wang X, Frappart L et al. Analysis of genetic variants of the poly(ADPribose) polymerase-1 gene in breast cancer in French patients. Mutat Res 2007; 632: 20-28.
40. Lockett KL, Hall MC, Xu J et al. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004; 64: 6344-6348.
41. Germain M, Affar EB, D'Amours D et al. Cleavage of automodified poly(ADPribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 1999; 274: 28379-28384.
42. Zaremba T, Thomas HD, Cole M et al. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J 2009; 101: 256-269.
43. Ghabreau L, Roux JP, Frappart PO et al. Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors. Int J Cancer 2004; 109: 317-321.
44. Idogawa M, Yamada T, Honda K et al. Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. Gastroenterology 2005; 128: 1919-1936.
45. Shimizu S, Nomura F, Tomonaga T et al. Expression of poly(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance. Oncol Rep 2004; 12: 821-825.
46. Graeser MK, McCarthy A, Lord CJ et al. A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010; 16: 6159-6168.
47. Kauppinen TM, Chan WY, Suh SW et al. Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. Proc Natl Acad Sci U S A 2006; 103: 7136-7141.
48. Kitamura T, Sekimata M, Kikuchi S, Homma Y. Involvement of poly(ADP-ribose) polymerase 1 in ERBB2 expression in rheumatoid synovial cells. Am J Physiol Cell Physiol 2005; 289: C82-C88.
49. Tentori L, Lacal PM, Muzi A et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 2007; 43: 2124-2133.
50. Rajesh M, Mukhopadhyay P, Batkai S et al. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun 2006; 350: 352-357.
51. Tentori L, Muzi A, Dorio AS et al. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur J Cancer 2008; 44: 1302-1314.
52. Elser M, Borsig L, Hassa PO et al. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol Cancer Res 2008; 6: 282-290.
53. Li M, Threadgill MD, Wang Y et al. Poly(ADP-ribose) polymerase inhibition downregulates expression of metastasis-related genes in CT26 colon carcinoma cells. Pathobiology 2009; 76: 108-116.
54. Tang L, Tron VA, Reed JC et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4: 1865-1871.